Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Cenicriviroc and Pioglitazone
NCT02342067Phase 1Completed
- Sponsor
- Tobira Therapeutics
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Tobira Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) of Cenicriviroc at Day 40, Area Under the Curve (AUC) of Cenicriviroc at Day 40 and 4 more. Started Dec 2014; status: completed.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02342067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342067.